Thank you for joining us at ASCO

Here's what we presented

Updated Guidelines

Newly updated ASCO Guidelines establish TAILORx-defined cutoffs for determining chemotherapy benefit in node-negative breast cancer and highlight the importance of testing with Oncotype DX for all medically-eligible breast cancer patients.

See the new guidelines →

New TAILORx Analysis in the New England Journal of Medicine

Dr. Sparano presented at ASCO 2019 his subset analysis of TAILORx and highlighted:
  • Only the Recurrence Score can determine chemotherapy benefit
  • Clinical and pathological features are prognostic and may be integrated with the Recurrence Score result to make treatment decisions in young patients with Recurrence Score results 16-25
Read the new analysis →

The New Oncotype DX Breast Recurrence Score Report

The newly designed report provides 3 points of clarity to aid in treatment decisions.

Learn more

Medicare Covers Oncotype DX AR-V7 Nucleus Detect Assay

Medicare coverage now provides metastatic castration-resistant prostate cancer (mCRPC) patients access to more definitive treatment options.

Learn more

Stay in Touch

Have a specific question? Want to keep up with our latest news? We're here for you.

Contact Us
Making cancer care smarter.™